一品红(300723.SZ)：全资子公司获得草酸艾司西酞普兰滴剂注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its drug, Escitalopram Oxalate Drops, which is indicated for the treatment of depression and panic disorder with or without agoraphobia [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Escitalopram Oxalate Drops [1] - The approved indication for the drug includes treatment for depression and panic disorder, with or without agoraphobia [1] Group 2: Mechanism of Action - Escitalopram is the S-enantiomer of racemic citalopram, and its antidepressant effect is believed to be related to the inhibition of serotonin (5-HT) reuptake in the central nervous system, thereby enhancing serotonergic activity [1] Group 3: Market Potential - The drug was registered as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] - According to data from Minet, the sales scale of Escitalopram in urban and county-level public hospitals in China is projected to be approximately 1,879.76 million RMB in 2024 [1]